Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 2/2014

01-04-2014 | Case Report

A case of fulminant liver failure associated with hepatitis C virus

Authors: Hiromitsu Kanzaki, Akinobu Takaki, Takahito Yagi, Fusao Ikeda, Tetsuya Yasunaka, Kazuko Koike, Yasuhiro Miyake, Yoshiaki Iwasaki, Kazuhiro Nouso, Hiroshi Sadamori, Susumu Shinoura, Yuzo Umeda, Ryuichi Yoshida, Masashi Utusmi, Toshiyoshi Fujiwara, Kazuhide Yamamoto

Published in: Clinical Journal of Gastroenterology | Issue 2/2014

Login to get access

Abstract

Fulminant hepatitis due to acute hepatitis C virus (HCV) infection is rarely observed. We present a case study of a 21-year-old male patient who developed HCV-associated fulminant hepatitis after receiving steroid pulse therapy for optic neuritis. Despite daily plasmapheresis, the disease progressed to irreversible liver failure with grade 3 hepatic encephalopathy by the 6th day after symptom onset. The patient received a liver transplant on the 8th day. Serum anti-HCV antibody was negative at that time, but became positive on the 12th day. Positive HCV RNA in the serum at admission was reported after transplantation. Positive changes in anti-HCV antibodies and acute hepatitis with massive necrosis in the histology of the explanted liver indicated fulminant hepatitis due to acute HCV infection. Because of severe hepatitis recurrence, he started 12 months of interferon therapy on the 48th day, and obtained sustained virological response. His anti-HCV antibodies became negative again by 1.5 years after cessation of therapy. HCV genomes recovered from the patient’s serum on the 7th and 48th days revealed 2 different clones out of 20 clones with 30 % amino acid difference in hypervariable region 1 of HCV second envelope glycoprotein. One of the 2 clones expanded further after liver transplantation. We conclude that early diagnosis of HCV-associated fulminant hepatitis requires the detection of HCV RNA in the serum. Severe hepatitis recurrence after liver transplantation might occur in patients with fulminant hepatitis due to HCV because of its monoclonal expansion.
Literature
1.
go back to reference Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama. 2001;55:133–59.PubMed Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama. 2001;55:133–59.PubMed
3.
go back to reference Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med. 1996;335:631–4.PubMedCrossRef Farci P, Alter HJ, Shimoda A, et al. Hepatitis C virus-associated fulminant hepatic failure. N Engl J Med. 1996;335:631–4.PubMedCrossRef
4.
go back to reference Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol. 2001;64:334–9.PubMedCrossRef Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol. 2001;64:334–9.PubMedCrossRef
5.
go back to reference Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288:339–44.PubMedCrossRef Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000;288:339–44.PubMedCrossRef
6.
go back to reference Oketani M, Ido A, Nakayama N, Intractable Hepato-Biliary Diseases Study Group of Japan, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.PubMedCrossRef Oketani M, Ido A, Nakayama N, Intractable Hepato-Biliary Diseases Study Group of Japan, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.PubMedCrossRef
7.
go back to reference Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–12.PubMedCrossRef Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–12.PubMedCrossRef
8.
go back to reference Saludes V, Esteve M, Casas I, et al. Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. J Clin Virol. 2013;57:263–6.PubMedCrossRef Saludes V, Esteve M, Casas I, et al. Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. J Clin Virol. 2013;57:263–6.PubMedCrossRef
9.
go back to reference Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014; 59:109-120. Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014; 59:109-120.
10.
go back to reference Kato N, Sekiya H, Ootsuyama Y, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993;67:3923–30.PubMedCentralPubMed Kato N, Sekiya H, Ootsuyama Y, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993;67:3923–30.PubMedCentralPubMed
11.
go back to reference Ray SC, Wang YM, Laeyendecker O, et al. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999;73:2938–46.PubMedCentralPubMed Ray SC, Wang YM, Laeyendecker O, et al. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999;73:2938–46.PubMedCentralPubMed
Metadata
Title
A case of fulminant liver failure associated with hepatitis C virus
Authors
Hiromitsu Kanzaki
Akinobu Takaki
Takahito Yagi
Fusao Ikeda
Tetsuya Yasunaka
Kazuko Koike
Yasuhiro Miyake
Yoshiaki Iwasaki
Kazuhiro Nouso
Hiroshi Sadamori
Susumu Shinoura
Yuzo Umeda
Ryuichi Yoshida
Masashi Utusmi
Toshiyoshi Fujiwara
Kazuhide Yamamoto
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 2/2014
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-014-0454-x

Other articles of this Issue 2/2014

Clinical Journal of Gastroenterology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine